{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T14:39:50Z","timestamp":1791470390585,"version":"4.3.4"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2024,9,14]],"date-time":"2024-09-14T00:00:00Z","timestamp":1726272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,9,14]],"date-time":"2024-09-14T00:00:00Z","timestamp":1726272000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Chemother Pharmacol"],"published-print":{"date-parts":[[2024,12]]},"DOI":"10.1007\/s00280-024-04716-x","type":"journal-article","created":{"date-parts":[[2024,9,14]],"date-time":"2024-09-14T02:01:55Z","timestamp":1726279315000},"page":"763-774","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Combination of S-1 and the oral ATR inhibitor ceralasertib is effective against pancreatic cancer cells"],"prefix":"10.1007","volume":"94","author":[{"given":"Yoshihito","family":"Morimoto","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kimihiko","family":"Takada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ami","family":"Nakano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Osamu","family":"Takeuchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuhiro","family":"Watanabe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masayoshi","family":"Hirohara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yutaka","family":"Masuda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,9,14]]},"reference":[{"key":"4716_CR1","doi-asserted-by":"publisher","first-page":"17","DOI":"10.3322\/caac.21763","volume":"73","author":"RL Siegel","year":"2023","unstructured":"Siegel RL, Miller KD, Wagle NS, Jemal A (2023) Cancer statistics, 2023. CA Cancer J Clin 73:17\u201348. https:\/\/doi.org\/10.3322\/caac.21763","journal-title":"CA Cancer J Clin"},{"key":"4716_CR2","doi-asserted-by":"publisher","first-page":"1817","DOI":"10.1056\/NEJMoa1011923","volume":"364","author":"T Conroy","year":"2011","unstructured":"Conroy T, Desseigne F, Ychou M, Bouch\u00e9 O, Guimbaud R, B\u00e9couarn Y, Adenis A, Raoul JL, Gourgou-Bourgade S, de la Fouchardi\u00e8re C, Bennouna J, Bachet JB, Khemissa-Akouz F, P\u00e9r\u00e9-Verg\u00e9 D, Delbaldo C, Assenat E, Chauffert B, Michel P, Montoto-Grillot C, Ducreux M (2011) FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med 364:1817\u20131825. https:\/\/doi.org\/10.1056\/NEJMoa1011923","journal-title":"N Engl J Med"},{"key":"4716_CR3","doi-asserted-by":"publisher","first-page":"1691","DOI":"10.1056\/NEJMoa1304369","volume":"369","author":"DD Von Hoff","year":"2013","unstructured":"Von Hoff DD, Ervin T, Arena FP, Chiorean EG, Infante J, Moore M, Seay T, Tjulandin SA, Ma WW, Saleh MN, Harris M, Reni M, Dowden S, Laheru D, Bahary N, Ramanathan RK, Tabernero J, Hidalgo M, Goldstein D, Van Cutsem E, Wei X, Iglesias J, Renschler MF (2013) Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med 369:1691\u20131703. https:\/\/doi.org\/10.1056\/NEJMoa1304369","journal-title":"N Engl J Med"},{"key":"4716_CR4","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1016\/s0140-6736(16)30583-9","volume":"388","author":"K Uesaka","year":"2016","unstructured":"Uesaka K, Boku N, Fukutomi A, Okamura Y, Konishi M, Matsumoto I, Kaneoka Y, Shimizu Y, Nakamori S, Sakamoto H, Morinaga S, Kainuma O, Imai K, Sata N, Hishinuma S, Ojima H, Yamaguchi R, Hirano S, Sudo T, Ohashi Y (2016) Adjuvant chemotherapy of S-1 versus gemcitabine for resected pancreatic cancer: a phase 3, open-label, randomised, non-inferiority trial (JASPAC 01). Lancet 388:248\u2013257. https:\/\/doi.org\/10.1016\/s0140-6736(16)30583-9","journal-title":"Lancet"},{"key":"4716_CR5","doi-asserted-by":"publisher","first-page":"1810","DOI":"10.1056\/NEJMoa072252","volume":"357","author":"S Sakuramoto","year":"2007","unstructured":"Sakuramoto S, Sasako M, Yamaguchi T, Kinoshita T, Fujii M, Nashimoto A, Furukawa H, Nakajima T, Ohashi Y, Imamura H, Higashino M, Yamamura Y, Kurita A, Arai K (2007) Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine. N Engl J Med 357:1810\u20131820. https:\/\/doi.org\/10.1056\/NEJMoa072252","journal-title":"N Engl J Med"},{"key":"4716_CR6","doi-asserted-by":"publisher","first-page":"624","DOI":"10.1093\/annonc\/mdx816","volume":"29","author":"Y Yamada","year":"2018","unstructured":"Yamada Y, Denda T, Gamoh M, Iwanaga I, Yuki S, Shimodaira H, Nakamura M, Yamaguchi T, Ohori H, Kobayashi K, Tsuda M, Kobayashi Y, Miyamoto Y, Kotake M, Shimada K, Sato A, Morita S, Takahashi S, Komatsu Y, Ishioka C (2018) S-1 and irinotecan plus bevacizumab versus mFOLFOX6 or CapeOX plus bevacizumab as first-line treatment in patients with metastatic colorectal cancer (TRICOLORE): a randomized, open-label, phase III, noninferiority trial. Ann Oncol 29:624\u2013631. https:\/\/doi.org\/10.1093\/annonc\/mdx816","journal-title":"Ann Oncol"},{"key":"4716_CR7","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1097\/00001813-199607000-00010","volume":"7","author":"T Shirasaka","year":"1996","unstructured":"Shirasaka T, Shimamato Y, Ohshimo H, Yamaguchi M, Kato T, Yonekura K, Fukushima M (1996) Development of a novel form of an oral 5-fluorouracil derivative (S-1) directed to the potentiation of the tumor selective cytotoxicity of 5-fluorouracil by two biochemical modulators. Anticancer Drugs 7:548\u2013557. https:\/\/doi.org\/10.1097\/00001813-199607000-00010","journal-title":"Anticancer Drugs"},{"key":"4716_CR8","first-page":"748","volume":"78","author":"K Tatsumi","year":"1987","unstructured":"Tatsumi K, Fukushima M, Shirasaka T, Fujii S (1987) Inhibitory effects of pyrimidine, barbituric acid and pyridine derivatives on 5-fluorouracil degradation in rat liver extracts. Jpn J Cancer Res 78:748\u2013755","journal-title":"Jpn J Cancer Res"},{"key":"4716_CR9","first-page":"2602","volume":"56","author":"T Shirasaka","year":"1996","unstructured":"Shirasaka T, Nakano K, Takechi T, Satake H, Uchida J, Fujioka A, Saito H, Okabe H, Oyama K, Takeda S, Unemi N, Fukushima M (1996) Antitumor activity of 1 M tegafur-0.4 M 5-chloro-2,4-dihydroxypyridine-1 M potassium oxonate (S-1) against human colon carcinoma orthotopically implanted into nude rats. Cancer Res 56:2602\u20132606","journal-title":"Cancer Res"},{"key":"4716_CR10","first-page":"4004","volume":"53","author":"T Shirasaka","year":"1993","unstructured":"Shirasaka T, Shimamoto Y, Fukushima M (1993) Inhibition by oxonic acid of gastrointestinal toxicity of 5-fluorouracil without loss of its antitumor activity in rats. Cancer Res 53:4004\u20134009","journal-title":"Cancer Res"},{"key":"4716_CR11","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1097\/CAD.0b013e328350e8c7","volume":"23","author":"Y Morimoto","year":"2012","unstructured":"Morimoto Y, Takeuchi O, Takizawa A, Yoneyama H, Asanuma F, Suzuki Y, Atsuda K, Yamada Y (2012) Effect of a combination of S-1 and gemcitabine on cell cycle regulation in pancreatic cancer cell lines. Anticancer Drugs 23:505\u2013514. https:\/\/doi.org\/10.1097\/CAD.0b013e328350e8c7","journal-title":"Anticancer Drugs"},{"key":"4716_CR12","doi-asserted-by":"publisher","first-page":"689","DOI":"10.3892\/or.2019.7421","volume":"43","author":"Y Morimoto","year":"2020","unstructured":"Morimoto Y, Takada K, Takeuchi O, Takagi A, Watanabe K, Hirohara M, Hamamoto T, Masuda Y (2020) Prexasertib increases the sensitivity of pancreatic cancer cells to gemcitabine and S-1. Oncol Rep 43:689\u2013699. https:\/\/doi.org\/10.3892\/or.2019.7421","journal-title":"Oncol Rep"},{"key":"4716_CR13","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1016\/j.radonc.2017.09.043","volume":"126","author":"Z Qiu","year":"2018","unstructured":"Qiu Z, Oleinick NL, Zhang J (2018) ATR\/CHK1 inhibitors and cancer therapy. Radiother Oncol 126:450\u2013464. https:\/\/doi.org\/10.1016\/j.radonc.2017.09.043","journal-title":"Radiother Oncol"},{"key":"4716_CR14","doi-asserted-by":"publisher","DOI":"10.1017\/erm.2020.3","volume":"22","author":"HL Smith","year":"2020","unstructured":"Smith HL, Southgate H, Tweddle DA, Curtin NJ (2020) DNA damage checkpoint kinases in cancer. Expert Rev Mol Med 22:e2. https:\/\/doi.org\/10.1017\/erm.2020.3","journal-title":"Expert Rev Mol Med"},{"key":"4716_CR15","doi-asserted-by":"publisher","first-page":"2709","DOI":"10.1111\/cas.15845","volume":"114","author":"K Yano","year":"2023","unstructured":"Yano K, Shiotani B (2023) Emerging strategies for cancer therapy by ATR inhibitors. Cancer Sci 114:2709\u20132721. https:\/\/doi.org\/10.1111\/cas.15845","journal-title":"Cancer Sci"},{"key":"4716_CR16","first-page":"2000","volume":"5","author":"K Hirata","year":"1999","unstructured":"Hirata K, Horikoshi N, Aiba K, Okazaki M, Denno R, Sasaki K, Nakano Y, Ishizuka H, Yamada Y, Uno S, Taguchi T, Shirasaka T (1999) Pharmacokinetic study of S-1, a novel oral fluorouracil antitumor drug. Clin Cancer Res 5:2000\u20132005","journal-title":"Clin Cancer Res"},{"key":"4716_CR17","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1158\/0008-5472.CAN-09-1947","volume":"70","author":"T-C Chou","year":"2010","unstructured":"Chou T-C (2010) Drug combination studies and their synergy quantification using the Chou-Talalay method. Cancer Res 70:440\u2013446. https:\/\/doi.org\/10.1158\/0008-5472.CAN-09-1947","journal-title":"Cancer Res"},{"key":"4716_CR18","doi-asserted-by":"publisher","first-page":"1211","DOI":"10.1007\/s00280-009-0990-0","volume":"64","author":"J Yoshizawa","year":"2009","unstructured":"Yoshizawa J, Takizawa A, Takeuchi O, Hiraku O, Sasaki K, Morimoto Y, Atsuda K, Inoue G, Suzuki Y, Asanuma F, Yamada Y (2009) Experimental study of combination therapy with S-1 against pancreatic cancer. Cancer Chemother Pharmacol 64:1211\u20131219. https:\/\/doi.org\/10.1007\/s00280-009-0990-0","journal-title":"Cancer Chemother Pharmacol"},{"key":"4716_CR19","doi-asserted-by":"publisher","first-page":"945","DOI":"10.4143\/crt.2020.080","volume":"52","author":"AR Nam","year":"2020","unstructured":"Nam AR, Jin MH, Bang JH, Oh KS, Seo HR, Oh DY, Bang YJ (2020) Inhibition of ATR Increases the Sensitivity to WEE1 Inhibitor in Biliary Tract Cancer. Cancer Res Treat 52:945\u2013956. https:\/\/doi.org\/10.4143\/crt.2020.080","journal-title":"Cancer Res Treat"},{"key":"4716_CR20","doi-asserted-by":"publisher","first-page":"764","DOI":"10.3892\/ijo.2018.4662","volume":"54","author":"K Suzuki","year":"2019","unstructured":"Suzuki K, Takeuchi O, Suzuki Y, Kitagawa Y (2019) Mechanisms of metformin\u2019s anti-tumor activity against gemcitabine-resistant pancreatic adenocarcinoma. Int J Oncol 54:764\u2013772. https:\/\/doi.org\/10.3892\/ijo.2018.4662","journal-title":"Int J Oncol"},{"key":"4716_CR21","doi-asserted-by":"publisher","first-page":"1195","DOI":"10.1111\/j.1349-7006.2012.02280.x","volume":"103","author":"H Goto","year":"2012","unstructured":"Goto H, Izawa I, Li P, Inagaki M (2012) Novel regulation of checkpoint kinase 1: Is checkpoint kinase 1 a good candidate for anti-cancer therapy? Cancer Sci 103:1195\u20131200. https:\/\/doi.org\/10.1111\/j.1349-7006.2012.02280.x","journal-title":"Cancer Sci"},{"key":"4716_CR22","doi-asserted-by":"publisher","first-page":"78","DOI":"10.3892\/or.2022.8289","volume":"47","author":"T Suzuki","year":"2022","unstructured":"Suzuki T, Hirokawa T, Maeda A, Harata S, Watanabe K, Yanagita T, Ushigome H, Nakai N, Maeda Y, Shiga K, Ogawa R, Mitsui A, Kimura M, Matsuo Y, Takahashi H, Takiguchi S (2022) ATR inhibitor AZD6738 increases the sensitivity of colorectal cancer cells to 5-fluorouracil by inhibiting repair of DNA damage. Oncol Rep 47:78. https:\/\/doi.org\/10.3892\/or.2022.8289","journal-title":"Oncol Rep"},{"key":"4716_CR23","doi-asserted-by":"publisher","first-page":"52","DOI":"10.3892\/or.2023.8489","volume":"49","author":"S Harata","year":"2023","unstructured":"Harata S, Suzuki T, Takahashi H, Hirokawa T, Kato A, Watanabe K, Yanagita T, Ushigome H, Shiga K, Ogawa R, Mitsui A, Kimura M, Matsuo Y, Takiguchi S (2023) AZD6738 promotes the tumor suppressive effects of trifluridine in colorectal cancer cells. Oncol Rep 49:52. https:\/\/doi.org\/10.3892\/or.2023.8489","journal-title":"Oncol Rep"},{"key":"4716_CR24","doi-asserted-by":"publisher","first-page":"2955","DOI":"10.3390\/cancers15112955","volume":"15","author":"F Keane","year":"2023","unstructured":"Keane F, O\u2019Connor CA, Park W, Seufferlein T, O\u2019Reilly EM (2023) Pancreatic cancer: BRCA targeted therapy and beyond. Cancers (Basel) 15:2955. https:\/\/doi.org\/10.3390\/cancers15112955","journal-title":"Cancers (Basel)"},{"key":"4716_CR25","doi-asserted-by":"publisher","first-page":"3929","DOI":"10.1200\/jco.21.01604","volume":"40","author":"HL Kindler","year":"2022","unstructured":"Kindler HL, Hammel P, Reni M, Van Cutsem E, Macarulla T, Hall MJ, Park JO, Hochhauser D, Arnold D, Oh DY, Reinacher-Schick A, Tortora G, Alg\u00fcl H, O\u2019Reilly EM, Bordia S, McGuinness D, Cui K, Locker GY, Golan T (2022) Overall survival results from the POLO trial: a phase III study of active maintenance olaparib versus placebo for germline BRCA-mutated metastatic pancreatic cancer. J Clin Oncol 40:3929\u20133939. https:\/\/doi.org\/10.1200\/jco.21.01604","journal-title":"J Clin Oncol"},{"key":"4716_CR26","doi-asserted-by":"publisher","first-page":"1205","DOI":"10.3390\/ijms23031205","volume":"23","author":"A Kasuga","year":"2022","unstructured":"Kasuga A, Okamoto T, Udagawa S, Mori C, Mie T, Furukawa T, Yamada Y, Takeda T, Matsuyama M, Sasaki T, Ozaka M, Ueki A, Sasahira N (2022) Molecular features and clinical management of hereditary pancreatic cancer syndromes and familial pancreatic cancer. Int J Mol Sci 23:1205. https:\/\/doi.org\/10.3390\/ijms23031205","journal-title":"Int J Mol Sci"},{"key":"4716_CR27","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1136\/gutjnl-2019-319970","volume":"70","author":"J Gout","year":"2021","unstructured":"Gout J, Perkhofer L, Morawe M, Arnold F, Ihle M, Biber S, Lange S, Roger E, Kraus JM, Stifter K, Hahn SA, Zamperone A, Engleitner T, M\u00fcller M, Walter K, Rodriguez-Aznar E, Sainz B Jr, Hermann PC, Hessmann E, M\u00fcller S, Azoitei N, Lechel A, Liebau S, Wagner M, Simeone DM, Kestler HA, Seufferlein T, Wiesm\u00fcller L, Rad R, Frappart PO, Kleger A (2021) Synergistic targeting and resistance to PARP inhibition in DNA damage repair-deficient pancreatic cancer. Gut 70:743\u2013760. https:\/\/doi.org\/10.1136\/gutjnl-2019-319970","journal-title":"Gut"},{"key":"4716_CR28","doi-asserted-by":"publisher","first-page":"4869","DOI":"10.1038\/s41388-020-1328-y","volume":"39","author":"RL Lloyd","year":"2020","unstructured":"Lloyd RL, Wijnhoven PWG, Ramos-Montoya A, Wilson Z, Illuzzi G, Falenta K, Jones GN, James N, Chabbert CD, Stott J, Dean E, Lau A, Young LA (2020) Combined PARP and ATR inhibition potentiates genome instability and cell death in ATM-deficient cancer cells. Oncogene 39:4869\u20134883. https:\/\/doi.org\/10.1038\/s41388-020-1328-y","journal-title":"Oncogene"},{"key":"4716_CR29","doi-asserted-by":"publisher","unstructured":"Mahdi H, Hafez N, Doroshow D, Sohal D, Keedy V, Do KT, LoRusso P, J\u00fcrgensmeier J, Avedissian M, Sklar J, Glover C, Felicetti B, Dean E, Mortimer P, Shapiro GI, Eder JP (2021) Ceralasertib-mediated ATR inhibition combined with olaparib in advanced cancers harboring DNA damage response and repair alterations (olaparib combinations). JCO Precis Oncol 5:PO.20.00439. https:\/\/doi.org\/10.1200\/po.20.00439","DOI":"10.1200\/po.20.00439"},{"key":"4716_CR30","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1016\/j.ygyno.2021.08.024","volume":"163","author":"PD Shah","year":"2021","unstructured":"Shah PD, Wethington SL, Pagan C, Latif N, Tanyi J, Martin LP, Morgan M, Burger RA, Haggerty A, Zarrin H, Rodriguez D, Domchek S, Drapkin R, Shih IM, Smith SA, Dean E, Gaillard S, Armstrong D, Torigian DA, Hwang WT, Giuntoli R, Simpkins F (2021) Combination ATR and PARP Inhibitor (CAPRI): a phase 2 study of ceralasertib plus olaparib in patients with recurrent, platinum-resistant epithelial ovarian cancer. Gynecol Oncol 163:246\u2013253. https:\/\/doi.org\/10.1016\/j.ygyno.2021.08.024","journal-title":"Gynecol Oncol"},{"key":"4716_CR31","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2022-005041","volume":"10","author":"M Kwon","year":"2022","unstructured":"Kwon M, Kim G, Kim R, Kim KT, Kim ST, Smith S, Mortimer PGS, Hong JY, Loemb\u00e9 AB, Irurzun-Arana I, Koulai L, Kim KM, Kang WK, Dean E, Park WY, Lee J (2022) Phase II study of ceralasertib (AZD6738) in combination with durvalumab in patients with advanced gastric cancer. J Immunother Cancer 10:e005041. https:\/\/doi.org\/10.1136\/jitc-2022-005041","journal-title":"J Immunother Cancer"},{"key":"4716_CR32","doi-asserted-by":"publisher","first-page":"5213","DOI":"10.1158\/1078-0432.Ccr-21-1032","volume":"27","author":"TA Yap","year":"2021","unstructured":"Yap TA, Krebs MG, Postel-Vinay S, El-Khouiery A, Soria JC, Lopez J, Berges A, Cheung SYA, Irurzun-Arana I, Goldwin A, Felicetti B, Jones GN, Lau A, Frewer P, Pierce AJ, Clack G, Stephens C, Smith SA, Dean E, Hollingsworth SJ (2021) Ceralasertib (AZD6738), an oral ATR kinase inhibitor, in combination with carboplatin in patients with advanced solid tumors: a phase I study. Clin Cancer Res 27:5213\u20135224. https:\/\/doi.org\/10.1158\/1078-0432.Ccr-21-1032","journal-title":"Clin Cancer Res"},{"key":"4716_CR33","doi-asserted-by":"publisher","first-page":"4700","DOI":"10.1158\/1078-0432.Ccr-21-0251","volume":"27","author":"ST Kim","year":"2021","unstructured":"Kim ST, Smith SA, Mortimer P, Loemb\u00e9 AB, Cho H, Kim KM, Smith C, Willis S, Irurzun-Arana I, Berges A, Hong JY, Park SH, Park JO, Park YS, Lim HY, Kang WK, Kozarewa I, Pierce AJ, Dean E, Lee J (2021) Phase I study of ceralasertib (AZD6738), a novel DNA damage repair agent, in combination with weekly paclitaxel in refractory cancer. Clin Cancer Res 27:4700\u20134709. https:\/\/doi.org\/10.1158\/1078-0432.Ccr-21-0251","journal-title":"Clin Cancer Res"}],"container-title":["Cancer Chemotherapy and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-024-04716-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00280-024-04716-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-024-04716-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,19]],"date-time":"2024-11-19T00:02:57Z","timestamp":1731974577000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00280-024-04716-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,14]]},"references-count":33,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2024,12]]}},"alternative-id":["4716"],"URL":"https:\/\/doi.org\/10.1007\/s00280-024-04716-x","relation":{},"ISSN":["0344-5704","1432-0843"],"issn-type":[{"value":"0344-5704","type":"print"},{"value":"1432-0843","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,9,14]]},"assertion":[{"value":"5 March 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 September 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 September 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interests"}},{"value":"The protocol of the animal experiments was reviewed and approved by the Animal Experiment Committee of Showa Pharmaceutical University on November 21, 2022 (approval no. 2022\u20131-R1), and the experiments were performed in accordance with the animal experiment regulations and manual of Showa Pharmaceutical University.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to publish"}}]}}